Trial intelligence / Profile preview

Treatment-free remission in chronic phase chronic myeloid leukemia with asciminib and tyrosine kinase inhibitors

KCT0009214Phase 2Not yet recruiting

Sponsor

Novartis

Start

Mar 2024

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1